AU2023221511A1 - Methods of treating blood disorders with vwf-targeted monospecific antibodies - Google Patents

Methods of treating blood disorders with vwf-targeted monospecific antibodies Download PDF

Info

Publication number
AU2023221511A1
AU2023221511A1 AU2023221511A AU2023221511A AU2023221511A1 AU 2023221511 A1 AU2023221511 A1 AU 2023221511A1 AU 2023221511 A AU2023221511 A AU 2023221511A AU 2023221511 A AU2023221511 A AU 2023221511A AU 2023221511 A1 AU2023221511 A1 AU 2023221511A1
Authority
AU
Australia
Prior art keywords
amino acid
acid sequence
seq
region
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023221511A
Other languages
English (en)
Inventor
Johan H. FABER
Prafull S GANDHI
Catherine REA
Benny SØRENSEN
Henrik ØSTERGAARD
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hemab Aps
Original Assignee
Hemab Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hemab Aps filed Critical Hemab Aps
Publication of AU2023221511A1 publication Critical patent/AU2023221511A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AU2023221511A 2022-02-15 2023-02-14 Methods of treating blood disorders with vwf-targeted monospecific antibodies Pending AU2023221511A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263268040P 2022-02-15 2022-02-15
US63/268,040 2022-02-15
US202263269000P 2022-03-08 2022-03-08
US63/269,000 2022-03-08
PCT/EP2023/053681 WO2023156409A1 (en) 2022-02-15 2023-02-14 Methods of treating blood disorders with vwf-targeted monospecific antibodies

Publications (1)

Publication Number Publication Date
AU2023221511A1 true AU2023221511A1 (en) 2024-09-12

Family

ID=85278579

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023221511A Pending AU2023221511A1 (en) 2022-02-15 2023-02-14 Methods of treating blood disorders with vwf-targeted monospecific antibodies

Country Status (8)

Country Link
US (1) US20250154283A1 (https=)
EP (1) EP4479435A1 (https=)
JP (1) JP2025507448A (https=)
KR (1) KR20240159860A (https=)
CN (1) CN119032109A (https=)
AU (1) AU2023221511A1 (https=)
CA (1) CA3244108A1 (https=)
WO (1) WO2023156409A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR133583A1 (es) * 2023-08-16 2025-10-15 Hemab Aps Métodos para tratar trastornos de la sangre con anticuerpos monoespecíficos dirigidos a vwf
WO2025174998A1 (en) * 2024-02-13 2025-08-21 Invetx, Inc. Anti-il-31ra antibodies and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201707139D0 (en) * 2017-05-04 2017-06-21 Imp Innovations Ltd Polypeptides

Also Published As

Publication number Publication date
EP4479435A1 (en) 2024-12-25
JP2025507448A (ja) 2025-03-18
WO2023156409A1 (en) 2023-08-24
US20250154283A1 (en) 2025-05-15
KR20240159860A (ko) 2024-11-06
CN119032109A (zh) 2024-11-26
CA3244108A1 (en) 2023-08-24

Similar Documents

Publication Publication Date Title
CA2747519C (en) Anti-fxi antibodies and methods of use
RU2588668C2 (ru) ПЕПТИД ИЛИ ПЕПТИДНЫЙ КОМПЛЕКС, СВЯЗЫВАЮЩИЙСЯ С альфа2-ИНТЕГРИНОМ, СПОСОБЫ ЕГО ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ УКАЗАННОГО ВЕЩЕСТВА
JP7051826B2 (ja) 凝固因子結合タンパク質及びその使用
JP7022081B2 (ja) 抗凝固因子ｘｉ抗体
US20250154283A1 (en) Methods of treating blood disorders with vwf-targeted monospecific antibodies
TW201605904A (zh) 治療凝血病變之新穎方法及抗體
JP7319721B2 (ja) 抗凝固因子ＸＩ活性型因子ＸＩａ抗体並びにその調製方法及び使用
US11542329B2 (en) Antibodies targeting Glycoprotein VI
KR20230147624A (ko) 면역조절 항체 및 이의 용도
CN113880949A (zh) 凝血因子xi(fxi)结合蛋白
CN113880951A (zh) 凝血因子xi(fxi)结合蛋白
AU2024324856A1 (en) Methods of treating blood disorders with vwf-targeted monospecific antibodies
HK40118720A (zh) 用靶向vwf的单特异性抗体治疗血液病症的方法
JP6445440B2 (ja) 抗プロテインｃ抗体による出血性疾患の治療
CN113880950A (zh) 凝血因子xi(fxi)结合蛋白
HK40084746A (en) Coagulation factor xi (fxi) binding protein
CN118414168A (zh) 因子xi a2结构域结合抗体和其使用方法